Compounded vasopressin syringes recalled as subpotent by IntegraDose Compounding Services
Vasopressin 2 Units/2 mL in 0.9% sodium chloride syringes from IntegraDose Compounding Services are being recalled as a subpotent drug. 287 units are affected.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall where a compounded injectable delivers less drug than labelled, a risk of harm with no injuries reported in the source.
Plain-English summary
Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride, supplied in a syringe by IntegraDose Compounding Services, LLC of Shoreview, Minnesota, NDC 71139-0190-1, is being recalled. The action covers 287 units.
The stated reason is a subpotent drug. The FDA classified the action as Class II.
Affected lots are 20260327VAS-3, beyond use date 05/26/2026, and 20260320VAS-3, beyond use date 05/19/2026. Distribution was USA nationwide. The syringes are supplied to healthcare facilities rather than sold to consumers.
Facilities should identify affected stock using the NDC and lot numbers above, quarantine it, and follow the instructions issued by IntegraDose.
The recalled product
- Product
- Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride, syringe, IntegraDose Compounding Services, LLC. 3650 Victoria St N, Suite 900, Shoreview, MN, NDC 71139-0190-1.
- Manufacturer
- IntegraDose Compounding Services LLC
- Category
- Drug — Compounded injectable
- Affected units
- 287
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot#: 20260327VAS-3
- BUD: 05/26/2026
- 20260320VAS-3
- BUD: 05/19/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · IntegraDose Compounding Services LLC
See all →- ModerateFentanyl Citrate Sterile Injection Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-05-27
- CriticalCompounded oxytocin bags recalled after testing found no oxytocin present
FDA (Drugs) · 2025-10-22
- HighFentanyl Citrate Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2024-04-10
- HighVasopressin Compounded Injectable Syringes Recalled for Sub-Potency Failure
FDA (Drugs) · 2024-02-21
- HighVasopressin Syringes Recalled for Subpotency by IntegraDose Compounding Services
FDA (Drugs) · 2024-01-31
Same hazard · subpotent
See all →- ModerateCAREone Earwax Removal Drops Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22
- ModerateSkin Rehab calming hydrocortisone balm recalled as a subpotent drug
FDA (Drugs) · 2026-04-22
- ModerateAvantor magnesium chloride active pharmaceutical ingredient recalled as subpotent
FDA (Drugs) · 2026-04-22
- ModerateRhonda Allison calming skin gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22
- Moderateglo Skin Beauty Remedy Gel recalled as a subpotent hydrocortisone product
FDA (Drugs) · 2026-04-22
Similar recalls
- HighVasopressin Syringes Recalled for Subpotency by IntegraDose Compounding Services
FDA (Drugs) · 2024-01-31
- HighVasopressin Compounded Injectable Syringes Recalled for Sub-Potency Failure
FDA (Drugs) · 2024-02-21
- SevereSCA Pharmaceuticals Recalls Subpotent Vasopressin Injection Bags
FDA (Drugs) · 2020-12-30
- CriticalCompounded oxytocin bags recalled after testing found no oxytocin present
FDA (Drugs) · 2025-10-22
- HighVasopressin Injectable Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-05-31
- ModerateFentanyl Citrate Sterile Injection Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-05-27